| Identification | Back Directory | [Name]
2-Azabicyclo[2.2.1]heptan-5-ol, 2-[2-[[(2-phenyl-4-thiazolyl)methyl]amino]-4-pyrimidinyl]- | [CAS]
3033646-06-6 | [Synonyms]
2-Azabicyclo[2.2.1]heptan-5-ol, 2-[2-[[(2-phenyl-4-thiazolyl)methyl]amino]-4-pyrimidinyl]- | [Molecular Formula]
C20H21N5OS | [MOL File]
3033646-06-6.mol | [Molecular Weight]
379.48 |
| Chemical Properties | Back Directory | [Boiling point ]
656.6±65.0 °C(predicted) | [density ]
1.394±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted) | [pka]
14.43±0.20(predicted) |
| Hazard Information | Back Directory | [Uses]
TACC3 inhibitor 1 is a potent and cross the blood-brain barrier TACC3 inhibitor. TACC3 inhibitor 1 induces Apoptosis and cell cycle arrest at G2/M phase. TACC3 inhibitor 1 induces the generation of intracellular ROS. TACC3 inhibitor 1 shows antiproliferative and anti-tumor activity[1]. | [in vivo]
TACC3 inhibitor 1 (20 mg/kg; i.p.; daily for 20 days) shows anti-tumor activity in mouse[1]. | Animal Model: | Six-week-old BALB/c nude mice (U87 xenograft model)[1] | | Dosage: | 20 mg/kg | | Administration: | I.p.; daily for 20 days | | Result: | Exhibited a significant tumor growth regression and no observable toxicity during the administration period and had no effects on the body weight. |
| [References]
[1] Zhao W, et al. Discovery of novel analogs of KHS101 as transforming acidic coiled coil containing protein 3 (TACC3) inhibitors for the treatment of glioblastoma. Eur J Med Chem. 2022 Dec 15;244:114874. DOI:10.1016/j.ejmech.2022.114874 |
|
|